3032920-98-9
Chemical Structure
JN-170
- CAS. Nr.: 3032920-98-9
- Formula:C20H21F3N6O2
- Molecular Weight:434.41
InChIKey: LNYJCHQINZNZAQ-IBGZPJMESA-N
SMILES: O=C(NCCC1(CC1)N)N2C[C@](C3=NC(C4=CC=C(C=C4)C#N)=NO3)(CC2)C(F)(F)F
Biological Activity: JN-170 is a potent and highly selective inhibitor and transport corrector of human SLC6A19 (IC50=47 nM). Furthermore, at a concentration of 35 μM, JN-170 exhibits no activity against SLC1A5, SLC7A5, or SLC6A8. JN-170 is applicable to research on phenylketonuria (PKU) and hyperphenylalaninemia. JN-170 is also suitable for studies related to various metabolic disorders, including tyrosinemia, maple syrup urine disease, urea cycle disorders, and hyperammonemia[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JN-170 | JN-170 is a potent and highly selective inhibitor and transport corrector of human SLC6A19 (IC50=47 nM). Furthermore, at a concentration of 35 μM, JN-170 exhibits no activity against SLC1A5, SLC7A5, or SLC6A8. JN-170 is applicable to research on phenylketonuria (PKU) and hyperphenylalaninemia. JN-170 is also suitable for studies related to various metabolic disorders, including tyrosinemia, maple syrup urine disease, urea cycle disorders, and hyperammonemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wobst HJ, et al. SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine. JCI Insight. 2024;9(21):e182876. Published 2024 Nov 8. [Content Brief]
- [2]. Ryan HA, et al. Treating pku with correctors of mammalian slc6a19 function. WO2024059005A1. 2023-09-11.
